Skip to main content
Egyptian Rheumatology and Rehabilitation
Download PDF

Assessment of serum antimutated citrullinated vimentin antibodies in rheumatoid arthritis

Egyptian Rheumatology and Rehabilitation volume 42, pages 62–67 (2015)Cite this article

An Erratum to this article was published on 01 April 2016

Abstract

Background

Early diagnosis and treatment of rheumatoid arthritis (RA) leads to better control and prevents irreversible joint damage. Antimutated citrullinated vimentin (anti-MCV) is one of the members of the anticitrullinated antibody family that can function as a serological marker in the early diagnosis of RA.

Aim of the work

This study aimed to measure serum levels of anti-MCV antibodies and study their relationship using clinical, laboratory, and radiological findings in RA patients.

Patients and methods

We measured anti-MCV in the serum of 60 RA patients, in 20 patients with psoriatic arthritis, and in 20 healthy controls. In RA patients, the disease activity score (DAS28) and the Health Assessment Questionnaire score were used. The immunoglobulin-M rheumatoid factor titer, anticyclic citrullinated peptide antibody (anti-CCP) titer, and C-reactive protein levels were also measured. The hands of RA patients were radiologically scored using the Larsen method.

Results

In RA patients the mean anti-MCV antibody serum level was 150.83 ± 125.95 U/ml, which was significantly higher (P < 0.001) compared with the mean serum level in psoriatic arthritis patients and healthy controls (17.4 ± 10.039 and 17.2 ± 10.63 U/ml, respectively). Serum levels of anti-MCV antibodies significantly correlated with DAS28 (r = 0.79, P < 0.05), Health Assessment Questionnaire scores (r = 0.53, P < 0.05), rheumatoid factor titer (r = 0.74, P < 0.05), anti-CCP antibody titer (r = 0.83, P < 0.05), and Larsen’s score (r = 0.76, P < 0.05).

Conclusion

The significantly elevated anti-MCV antibody levels that are well correlated with RA disease activity and severity markers are highly suggestive of their potential role in the pathogenesis of RA. The considerable correlation of anti-MCV antibodies with other autoantibodies would imply their consistent diagnostic and prognostic role.

References

  1. Gravallese E. Bone destruction in arthritis. Ann Rheum Dis 2002; 61:ii84–ii86.

    Article  Google Scholar 

  2. Orozco C, Olsen NJ. Identification of patients with early rheumatoid arthritis: challenges and future directions. Clin Dev Immunol 2006; 13:295–297.

    Article  CAS  Google Scholar 

  3. Taylor P, Gartemann J, Hsieh J, Creeden J. A systematic review of serum biomarkers anti-cyclic citrullinated peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis 2011; 2011:815038.

    Google Scholar 

  4. Riedmann JP, Munoz S, Kavanaugh A. The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis — a systematic review. Clin Exp Rheumatol 2005; 23:S69–S76.

    Google Scholar 

  5. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001; 166:4177–4184.

    Article  CAS  Google Scholar 

  6. Chang X, Yamada R, Suzuki A, Kochi Y, Sawada T, Yamamoto K. Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology 2005; 44:1374–1382.

    Article  CAS  Google Scholar 

  7. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005; 7:R1421–R1429.

    Article  CAS  Google Scholar 

  8. Agrawal S, Misra R, Aggarwal A. Auto-antibodies in rheumatoid arthritis; association with severity of disease in established RA. Clin Rheumatol 2007; 26:201–204.

    Article  Google Scholar 

  9. Vossenar ER, Radstake TR, van der Heijden A, van Mansum MA, Dieteren C, de Rooij DJ, et al. Expression and activity of citrullinating peptidyl argininedeiminase enzymes in monocytes and macrophages. Ann Rheum Dis 2004; 63:373–381.

    Article  Google Scholar 

  10. Strelkov SV, Herrmann H, Aebi U. Molecular architecture of intermediate filaments. Bioassays 2003; 25:243–251.

    Article  CAS  Google Scholar 

  11. Sghiri R, Bouajina E, Bargaoui D, Harzallah L, Fredj HB, Sammoud S, et al. Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis. Rheumatol Int 2008; 29:59–62.

    Article  CAS  Google Scholar 

  12. Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L, et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic vale concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008; 58:36–45.

    Article  CAS  Google Scholar 

  13. van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis and rheumatism.”Arthritis Rheum 2009; 60:2232–41.

    Article  Google Scholar 

  14. Dejaco C, Kotz W, Larcher H, Duftner C, Schirmer M, Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006; 8:R119.

    Article  Google Scholar 

  15. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism. Arthritis Rheum 2010; 62:2569–2581.

    Article  Google Scholar 

  16. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54:2665– 2673.

    Article  Google Scholar 

  17. Prevoo ML, van’t HMA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38:44–48.

    Article  CAS  Google Scholar 

  18. Bruce B, Fries J. The Stanford health assessment questionnaire (HAQ): a review of its history, issues, progress, and documentation. J Rheumatol 2003; 30:167–178.

    PubMed  Google Scholar 

  19. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by reference films. Acta Radiol Diagn 1977; 18:481–491.

    Article  CAS  Google Scholar 

  20. Westergren A. Studies of suspension stability of the blood in pulmonary tuberculosis. Am Rev Tuberc 1921; 14:94.

    Google Scholar 

  21. Genevay S, Hayem G, Verpillat P, Meyer O. An eight year prospective study of outcome prediction by antiperinuclear factor and antikeratin antibodies at onset of rheumatoid arthritis. Ann Rheum Dis 2002’ 61:734–736.

    Article  CAS  Google Scholar 

  22. Vencovský J, Machácek S, Sedová L, Kafková J, Gatterová J, Pesáková V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003; 62:427–430.

    Article  Google Scholar 

  23. Gonzalez-Lopez L, Rocha-Muñoz AD, Ponce-Guarneros M, Flores-Chavez A, Salazar-Paramo M, Nava A, et al. Anti-cyclic citrullinated peptide (anti-CCP) and anti-mutated citrullinatedvimentin (anti-MCV) relation with extra-articular manifestations in rheumatoid arthritis. J Immunol Res 2014; 2014:536050.

    Google Scholar 

  24. Mansour HE, Metwalt KM, Hassan IA, Elshamy HA, Elbeblawy MM. Antibody to mutated citrullinatedvimentin in rheumatoid arthritis: diagnosticvalue, association with radiological damage and axial skeleton affection. Clin Med Insight Arthritis Musculoskelet Disord 2010; 3:33–42.

    Article  Google Scholar 

  25. Tesija-Kuna A, Grazio S, Miler M, Vukasovic I, Peric P, Vrkic N. Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis. Clin Rheumatol 2010; 29:487–493.

    Article  Google Scholar 

  26. Keskin G, Inal A, Keskin D, Pekel A, Baysal O, Dizer U, et al. Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis. Protein Pept Lett 2008; 15:314–317.

    Article  CAS  Google Scholar 

  27. Ursum J, Nielen MM, van Schaardenburg D, van der Horst AR, van de Stadt RJ, Dijkmans BA, et al. Antibodies to mutated citrulinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 2008; 10:R12.

    Article  Google Scholar 

  28. Roland PN, Mignot SG, Bruns A, Hurtado M, Palazzo E, Hayem G, et al. Antibodies to mutated citrulinated vimentin for diagnosing rheumatoid arthritis in anti CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther 2008; 10:R142.

    Article  Google Scholar 

  29. Dieudé P, Garnier S, Michou L, Petit-Teixeira E, Glikmans E, Pierlot C, et al. Rheumatoid arthritis seropositive for rheumatoid factor is linked to protein tyrosine phosphatase nonreceptor 22-620w allele. Arthritis Res Ther 2005; 7:R1200–R1207.

    Article  Google Scholar 

  30. Kokkonen H, Johansson M, Innala L, Jidell E, Rantapää-Dahlqvist S. The PTPN22 1858 C/T polymorphism is associated with anti cycliccitrulinated peptide antibody positive early rheumatoid arthritis in northern Sweden. Arthritis Res Ther 2007; 9:R56.

    Article  Google Scholar 

  31. Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008; 35:1002–1008.

    PubMed  Google Scholar 

  32. Syversen SW, Gaarder PI, Goll GL, Ødegård S, Haavardsholm EA, Mowinckel P et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008; 67:212–217.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Physical Medicine, Rheumatology and Rehabilitation, Benha University Hospital, 5 Ahmed Salem Street, Benha, Egypt

    Refaat M. El Tanawy, Khaled M. Belal, Waleed A. Hassan MD, Emtesal A. Said & Shaimaa M. Hafez

Authors
  1. Refaat M. El Tanawy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Khaled M. Belal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Waleed A. Hassan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emtesal A. Said
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shaimaa M. Hafez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Waleed A. Hassan MD.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El Tanawy, R.M., Belal, K.M., Hassan, W.A. et al. Assessment of serum antimutated citrullinated vimentin antibodies in rheumatoid arthritis. Egypt Rheumatol Rehabil 42, 62–67 (2015). https://doi.org/10.4103/1110-161X.157862

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/1110-161X.157862

Keywords